Is Osimertinib on the market?

Osimertinib (Osimertinib) is a drug used to treat non-small cell lung cancer with specific mutations. Common trade name is Tagrisso. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Osimertinib was approved for medical use by the U.S. Food and Drug Administration (FDA) in November 2015 and in the European Union in February 2016.

Osimertinib is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the cancer cells are positive for the T790M mutation in the gene encoding EGFR or activating EGFR mutations. The T790M mutation may be de novo or acquired after first-line treatment with other EGFR tyrosine kinase inhibitors (such as gefitinib, erlotinib, and afatinib). In the United States, patients must be tested for EGFR exon 19 deletion, exon 21 L858R mutation, or T790M status through a companion diagnostic test before treatment with osimertinib. In Europe and elsewhere, activating EGFR mutations or T790M mutations can be identified through confirmatory testing.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.